ERBB2 and triple-negative breast carcinoma: Patients with triple-negative breast cancer (TNBC), clinically defined by their minimal expression or absence of estrogen receptor, progesterone receptor, and receptor tyrosine-protein kinase erbB-2 (HER2), have poor prognosis due to the lack of effective molecular targeting therapies (1, 2).